3/17/2014 chart update (daily)
Description
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company’s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.
Address
Two Corporate Drive
SOUTH SAN FRANCISCO, CA 94080
United States
SOUTH SAN FRANCISCO, CA 94080
United States
Website
http://www.fiveprime.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -207.75% | -276.42% |
| Operating margin | -210.17% | -278.51% |
| EBITD margin | - | -262.06% |
| Return on average assets | -45.55% | -53.75% |
| Return on average equity | - | - |
| Employees | 107 |
No comments:
Post a Comment